To provide insights into the pathogenesis of DiamondBlackfan anemia, we examined the in vitro response of erythroid progenitors to the recently isolated ligand for c-kit (stem cell factor, SCF). For these studies, marrow or blood mononuclear cells from 10 Diamond-blackfan patients were cultured with erythropoietin (Ep), Ep and interleukin-3, Ep and granulocyte-macrophage colony-stimulating factor, or Ep and lymphocyte conditioned media (LCM). These combinations were tested in the presence or absence of SCF. The majority (70%) of patients with Diamond-Blackfan anemia do not have other congenital anomalies; thus, this disease must be clinically distinguished from transient erythroblastosis of childhood (TEC), acquired (often immunologically mediated) pure RBC aplasia (PRCA), chronic B19 patvovirus infection, and myelodysplasia. In about 75% of the patients, the anemia responds to prednisone,' often at extremely low doses, suggesting that ambient steroids can improve the abnormal RBC production. Prednisone nonresponding patients have been cured with marrow transplant a t i~n .~ In other individuals, erythropoiesis has improved with granulocyte-macrophage colony-stimulating factor (GM-CSF) or interleukin-3 (IL-3) therapy: This natural history, as well as marrow culture suggests that the disease could result from an abnormality of a hematopoi- from all patients responded, there were differences among individuals in the sensitivity of their BFU-E to SCF. In six patients and all control studies, plateau frequencies of erythroid bursts were achieved with I 10 ng/mL SCF, whereas in studies from the other four patients, over 50 ng/mL SCF was required. These data invite speculation that the c-kit receptor/ligand axis is involved in the pathogenesis of DiamondBlackfan anemia. More importantly and regardless of whether the observed patterns of response reflect the primary defect or an epiphenomenon, our data strongly support a therapeutic trial of SCF in patients with Diamond-Blackfan anemia.
To provide insights into the pathogenesis of DiamondBlackfan anemia, we examined the in vitro response of erythroid progenitors to the recently isolated ligand for c-kit (stem cell factor, SCF). For these studies, marrow or blood mononuclear cells from 10 Diamond-blackfan patients were cultured with erythropoietin (Ep), Ep and interleukin-3, Ep and granulocyte-macrophage colony-stimulating factor, or Ep and lymphocyte conditioned media (LCM). These combinations were tested in the presence or absence of SCF. The mean number of cells per erythroid burst increased 5 to 50-fold in cultures containing SCP. Furthermore, many additional erythroid bursts were seen (mean increment 3.
x baseline values). Although burst-forming unit-erythroid (BFU-E)
IAMOND-BLACKFAN anemia is a congenital disor-D der of erythropoiesis.'.' Patients are severely anemic, the reticulocytes are decreased, and few, often megaloblastoid, erythroid precursors are seen in marrow aspirates.
Residual red blood cells (RBCs) have high mean cell volumes (MCV) and may have excess adenosine deaminase or higher levels of fetal hemoglobin or i antigen. The morphology and number of megakaryocytic and granulocytic cells in the marrow and in the circulation are normal.
The majority (70%) of patients with Diamond-Blackfan anemia do not have other congenital anomalies; thus, this disease must be clinically distinguished from transient erythroblastosis of childhood (TEC), acquired (often immunologically mediated) pure RBC aplasia (PRCA), chronic B19 patvovirus infection, and myelodysplasia. In about 75% of the patients, the anemia responds to prednisone,' often at extremely low doses, suggesting that ambient steroids can improve the abnormal RBC production. Prednisone nonresponding patients have been cured with marrow transplant a t i~n .~ In other individuals, erythropoiesis has improved with granulocyte-macrophage colony-stimulating factor (GM-CSF) or interleukin-3 (IL-3) therapy: This natural history, as well as marrow culture suggests that the disease could result from an abnormality of a hematopoi-from all patients responded, there were differences among individuals in the sensitivity of their BFU-E to SCF. In six patients and all control studies, plateau frequencies of erythroid bursts were achieved with I 10 ng/mL SCF, whereas in studies from the other four patients, over 50 ng/mL SCF was required. These data invite speculation that the c-kit receptor/ligand axis is involved in the pathogenesis of DiamondBlackfan anemia. More importantly and regardless of whether the observed patterns of response reflect the primary defect or an epiphenomenon, our data strongly support a therapeutic trial of SCF in patients with Diamond-Blackfan anemia.
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etic progenitor cell and/or the marrow microenvironment in which it differentiates.
Mutations at the white spotting (W) or steel (SI) locus in mice result in a clinical syndrome similar to DiamondBlackfan anemia.'' There is a macrocytic anemia, reduced numbers of reticulocytes, and normal granulocyte and platelet counts. Certain W and S1 mutations are also associated with abnormalities of pigmentation and fertility. Mice with abnormalities at the W locus have defective stem cells, but a normal hematopoietic micr~environment.'~ Steel mice have the reciprocal defect, an abnormality in microenvironmental cells.14 Recently, it has been shown that the W locus is allelic with c-kit. This proto-oncogene encodes a transmembrane tyrosine kinase that is structurally similar to the plateletderived growth factor receptor and the CSF-1 receptor. Missense and deletion mutations of the c-kit coding sequence have been d e~c r i b e d .~~~'~ Other W mutations result in decreased expression of c-kit protein.I6 S1 mutations result in abnormalities in the ligand for the c-kit receptor, stem cell factor (SCF; or kit-ligand [KL] ), which is produced by fibroblasts, including marrow stromal cell^."^*^ To derive insights into the pathogenesis of DiamondBlackfan anemia, patients' marrow or blood cells were cultured in the presence of various concentrations of recombinant human SCF." The response to SCF was compared with that of normals, and of transfused individuals with acquired PRCA, TEC, or a 5q-cytogenetic abnormality presenting as refractory anemia. The numbers and sizes of erythroid bursts cultured from DiamondBlackfan patients increased dramatically in response to SCF. These results may have clinical implications.
MATERIALS AND METHODS
Subjects. Marrows were obtained from the posterior iliac crest or blood by venipuncture after informed consent, using protocols approved by the Human Subjects Division of the University of Washington (Seattle). The 10 patients had hematologic criteria of Diamond-Blackfan and marrow karyotypes were normal. Patient 6 had triphalangeal thumbs characteristic of the Aase syndrome.' Clinical data are presented in Table 1 . At the time of study, patients 1 through 3 and 6 through 10 were severely anemic with elevated MCVs (> 115). Platelet and white blood cell counts Patients 2,3, and 7 were steroid-responsive for several years early in the course of their disease. Patient 4 required a high-dose prednisone during childhood, resulting in aseptic necrosis of a femoral head, but with adolescence (age 13), her anemia remitted. The anemia in patient 5 improved during her pregnancies. The anemia in patients 1,6, and 8 was unresponsive to Ig, cyclosporine, and/or cyclophosphamide. Patient 5 had an atypical presentation. She was noted to have a macrocytic anemia or routine exam at age 26. There were no previous CBC values. Diagnosis was established at age 35. At that time her hematocrit = 17, MCV = 119, reticulocyte index = 0.3, and marrow E/G = 0.1 with megaloblastic erythropoiesis. 20% of circulating RBCs contained hemoglobin F. White blood cell count, platelet count, folate, 612, sucrose hemolysis studies, and marrow cytogenetics were negative or normal. Patient 7 was anemic since birth and required 31 transfusions before age 8, but a diagnosis was not established until age 22. Chromosome fragility studies were performed for patients 6,9, and 10 and were normal. When tested (patients 1,2, and 5), B19 parvovirus was not present in the serum with polymerase chain reaction and Southern analyses (personal communication, N. Frickhofen and N. Young, Bethesda, MD).
Hemoglobin F (HbF) was quantitated by alkaline denaturation or the percentage of F cells determined with immunofluorescence. Values > 2% HbF or > 10% F cells, respectively, were considered increased ( t ). ND, not done.
were normal and marrow smears showed erythroid hypoplasia (erythroid/granulocytic [E/G] < O.l), often with residual megaloblastoid erythropoiesis. Patient 4, in remission (hematocrit = 38) since adolescence, had relative erythroid hypoplasia (E/G = 0.2), a high erythropoietin (Ep) level (300 mU/mL) and a normal MCV (91). Her 3-year-old daughter (patient 9) has Diamond-Blackfan anemia. A familial incidence of Diamond-Blackfan anemia was also reported by patients 8 and 10. Blood was obtained from patient 5 when she was 3 months pregnant. Her hematocrit was 28 and MCV 118. Marrow and/or blood were also obtained from healthy volunteers (ages 24 to 35), and control patients with PRCA, TEC, or the 5q-syndrome with erythroid hypoplasia.
Light-density mononuclear cells (10s marrow cells/mL or 1 to 6 x 10s blood cells/mL) were cultured using published methods.23 In some experiments, monocytes were depleted by adherence to plastic for 2 hours or overnight. Other studies used cells previously frozen in 5% dimethyl sulfoxide, 95% fetal calf serum, and stored in liquid nitrogen. Cultures were supplemented with various concentrations of human recombinant (hr) E p (AMGEN, Thousand Oaks, CA), hr IL-3 (Genetics Institute, Boston, MA), hr GM-CSF (provided by Kenneth Kaushansky, University of Washington,, Seattle), lymphocyte-conditioned medium (LCM), supernatant from phytohemagglutin stimulated peripheral blood cells,2" and/or hr SCF (AMGEN). After 13 to 14 or 20 to 21 days of incubation at 37°C in high humidity and 4% CO, erythroid bursts (with over 200 cells) and GM colonies (with over 50 cells) were enumerated.
To determine the mean number of erythroid cells per burst, bursts were individually removed from cultures with micropipets under direct vision with an inverted microscope, pooled, washed with phosphate-buffered saline, and then counted. Results are expressed as the total number of cells recovered divided by the number of bursts. To eliminate selection bias, all bursts on given plates were analyzed.
Marrow culture.

RESULTS
Marrow mononuclear cells were studied from patients 1 through 4. Low to normal frequencies of burst-forming unit-erythroid (BFU-E) and colony-forming unit-GM (CFU-GM) were detected per lo5 mononuclear cells (ranges 15 to 62 and 2 to 82, respectively) plated in methylcellulose culture in the presence of Ep (1 to 5 U/mL) and IL-3 (1 to 2 U/mL), GM-CSF (> 100 U/mL), or LCM 2% to 5%. Full dose-response curves (done for patients 1, 2, and 4) to Ep or IL-3 (with 1 U/mL Ep) showed "plateau" BFU-E responses occurred at factor concentrations similar to those in normal individuals (data not shown). No additional bursts were seen with up to 20 U/mL Ep or 20 U/mL IL-3. The magnitudes of growth factor response varied and can be estimated from the data in Table 2 . Only blood cells were available for study in patients 5 through 10. BFU-E growth was poor ( < 10 per 5 x lo5) despite up to 20 U/mL Ep or 1,OOO U/mL IL-3 (data not shown). Table 2 and Fig 1 show responses of marrow BFU-E from Diamond-Blackfan patients and controls to SCF. Although each preparation of marrow (fresh mononuclear cells, cells after overnight adherence, cells previously frozen in liquid nitrogen) yielded different frequencies of progenitors, incremental responses to SCF were remarkably similar ( Table  2 ). Similarities were evident in marrow studies from different individuals as well as on the repeated studies of normal control 3. In normal individuals, little increase in the number of erythroid bursts was seen when SCF (100 ng/mL) was added to cultures of marrow mononuclear cells in the presence of Ep alone, Ep + IL-3, Ep + GM-CSF, or Ep + LCM (mean increment = 1.5 2 0.3 [SD] x baseline in 17 studies from four individuals). Each dose-response curve showed a plateau response in frequencies of bursts (representative studies, Fig 1) and GM colonies (data not shown) at SCF concentrations of 2.5 to 10 ng/mL, consistent with prior data with murine SCF." Similar results were seen with marrow cells from two patients with acquired PRCA, one patient with TEC, and two patients with a 5q- bigger in size (see Table 4 ), suggesting amplification of BFU-E or their early progeny during the incubation time.
When marrow ( Table 2 ) or blood (Table 3 ) mononuclear cells from patients with Diamond-Blackfan anemia were cultured with SCF, there were significant increments in the frequency of erythroid bursts (eg, mean increment 3.2 * 1.0
[SD] x baseline BFU-E frequency, n = 16 marrow studies with or without 100 ng SCF/mL). Two patterns were seen. In five individuals (patients 2 through 5 and 9), the maximum frequencies of BFU-E (and CFU-GM) occurred with I 10 ng/mL SCF (eg, Table 3 , Fig l) , as seen in control studies. A similar result is likely in patient 7. In the four other patients (1, 6, 8, and lo), there was a shift in the dose-response curve so that maximal BFU-E (and CFU-GM) frequencies were observed with 2 5 0 ng/mL SCF (Table 3, Fig 1) . In both Diamond-Blackfan patients and controls, the size of erythroid bursts increased with increasing concentrations of SCF through 200 ng/mL (Table 4) . This was not a nonspecific response to growth factors, as parallel studies in patient 4 with IL-3 at concentrations of 50, 100, 200, and 500 U/mL yielded 1,780, 850, 970, and 2,010 cells per erythroid burst, respectively.
DISCUSSION
It is likely that Diamond-Blackfan anemia is a heterogeneous disorder. In vitro cultures have been previously used to provide insights into its pathogenesis.'." The frequencies of BFU-E and CFU-GM, although generally low, may be normal or high, especially early in the course of disease. Whether this is due to disease progression or the effects of therapy is not Previous investigators have reported that BFU-E required high concentrations of or IL-34 for optimal in vitro growth. This was not evident in our studies with up to 20 U/mL Ep or 1,000 U/mL IL-3, and may reflect the effects of crude preparations of Ep in some prior studies? Serum and cellular inhibitors of erythropoiesis have also been described?' but these in vitro abnormalities may be due to alloimmunization from prior transfusions. For this reason, multiply transfused patients with acquired PRCA or the 5q-myelodysplasic syndrome were studied as controls.
In our experiments, SCF was added to cultures of marrow or blood mononuclear cells from patients with Diamond-Blackfan anemia. Large increments in the number, as well as size, of erythroid bursts were seen. With 100 ng/mL SCF, the frequencies of BFU-E in culture were 3 . 2~ that without SCF (Tables 2 and 3 ). Furthermore, with added SCF, the mean number of cells per erythroid burst increased 5-to 50-fold ( Table 4 ).
The importance of the c-kit receptor and its ligand, SCF, in hematopoiesis has been established with delineation of the molecular defects in W and S1 mice. Mutations of either receptor or ligand result in a macrocytic anemia and low reticulocyte count.
Because the molecular basis of these abnormalities has been elucidated, there has been an interest in determining if diseases exist in humans with a similar pathogenesis. It is possible that some Diamond-Blackfan patients (eg, patients 2 through 5,7,9; pattern l, Fig l) have microenvironmental (eg, KL) defects. Decreased or functionally abnormal SCF in vivo would result in few BFU-E per 10' marrow or blood mononuclear cells. In methylcellulose culture with exogenous (normal) SCF, some additional cells might be recruited that could differentiate in response to Ep and growth factors to form hemoglobinized bursts. Patients (1, 6, 8 , and 10) with right-shifted SCF dose-response curves (pattern 2, Fig 1) could have abnormalities of c-kit receptor. With this physiology, frequencies of BFU-E could be low because of the intrinsic stem cell defect.
A unique clinical feature of Diamond-Blackfan anemia is its response to prednisone, often at extremely low doses. Also, as in patients 4 and 6, remissions may occur with adolescence or with pregnancies. This raises the possibility that the response of progenitor cells," or perhaps more likely SCF production by marrow stromal cells, is influenced by steroids or other hormones.
Interestingly, both c-kit and SCF proteins exist as dimers. In mice, homozygous deletion mutations (eg, Sld/Sld, W/W) are uniformly fatal, yet mice heterozygous for one deleted and one normal allele (Sld/+, W/+) have minimal hematologic abnormalitie~.'~~'~~'~ As the W allele encodes a truncated c-kit protein that is not expressed at the cell ~urface,'~ W/+ heterozygotes form fewer, yet normal c-kit dimers. Heterozygotes for a W missense mutation and a normal allele are more severely affected.l5.l6 In this circumstance, c-kit dimers can form with abnormal and normal component proteins and then function aberrantly. Analogous defects in Diamond-Blackfan patients could account for the varied inheritance of the anemia. Cases of DiamondBlackfan anemia occur sporadically, although rare familial incidence with dominant or recessive inheritance patterns have been described. ' Any proposition that abnormalities of c-kit receptor and its ligand characterize Diamond-Blackfan anemia remains speculative. Although consistent with our current data, molecular confirmation is required. Such studies are com- Mean numbers of cells per erythroid burst from normal controls (nos. 5 and 6). a TEC patient (no. I), and patients nos. 4, 7, 9, and IO) with Diamond-Blackfan anemia are shown for each concentration of SCF. To obtain sufficient numbers of colonies for studies in patient no. 10, bursts were pooled from plates with 0 to 100 ng/mL SCF and from plates with 500 to 1,000 ng/mL SCF.
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More importantly and regardless of whether abnormalities are found, our data show a major effect of SCF on the in vitro differentiation of BFU-E from all Diamond-Blackfan Patients. Both the numbers of detectable BFU-E and the numbers of erythroid cells deriving from each BFU-E increased with SCF. Therefore, a therapeutic trial of this growth factor in patients with Diamond-Blackfan anemia seems warranted.
